earnings
confidence high
sentiment positive
materiality 0.75
OptimizeRx Q4 revenue $20.3M (+24% YoY), FY revenue $61.3M (+42%), guides FY22 $80-85M
OptimizeRx Corp
2021-FY EPS reported
$0.02
revenue$61,292,598
- Q4 GAAP net income $0.6M ($0.04 diluted EPS); non-GAAP net income $4.0M ($0.22 diluted EPS).
- Gross margin improved to 61% in Q4 from 52.4% a year ago.
- Introduced KPIs: avg revenue per top-20 pharma client $2.5M, 95% penetration, net revenue retention 127%.
- FY22 guidance: revenue $80-85M (+31-39% YoY), gross margin 57-60%.
- Cash and equivalents $84.7M at Dec 31, 2021; cash flow positive from operations $0.7M in FY21.